Publication: The effects of acetylcholinesterase inhibitors on morbidity after general anesthesia and surgery
Issued Date
2020-08-15
Resource Type
ISSN
18737064
00283908
00283908
Other identifier(s)
2-s2.0-85085035936
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Neuropharmacology. Vol.173, (2020)
Suggested Citation
Denys Shaydenfish, Karuna Wongtangman, Matthias Eikermann, Maximilian S. Schaefer The effects of acetylcholinesterase inhibitors on morbidity after general anesthesia and surgery. Neuropharmacology. Vol.173, (2020). doi:10.1016/j.neuropharm.2020.108134 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/56335
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The effects of acetylcholinesterase inhibitors on morbidity after general anesthesia and surgery
Abstract
© 2020 Elsevier Ltd Non-depolarizing neuromuscular blocking agents are used during general anesthesia to facilitate intubation and optimize surgical conditions. When patients leave the operating room after surgery, postoperative residual neuromuscular block occurs frequently, increasing vulnerability to respiratory complications such as hypoxemia and unplanned postoperative mechanical ventilation. To restore neuromuscular transmission and skeletal muscle strength, anesthesiologists typically administer peripherally acting acetylcholinesterase inhibitors such as neostigmine. However, neostigmine's desirable effects have a narrow therapeutic range. Even at recommended dose (15–50 μg/kg), neostigmine induces nicotinic (upper airway muscle weakness leading to dysphagia and upper airway obstruction, and decreased maximum inspiratory airflow) and muscarinic (blurred vision, bronchial constriction, abdominal cramping and nausea) side effects. Recent data have questioned as to whether neostigmine reversal of neuromuscular blockade improves relevant patient outcomes such as postoperative respiratory and perioperative cardiovascular complications. A central strategy to avoid side effects of neuromuscular blocking agents is their judicious use based on quantitative monitoring of neuromuscular transmission using repetitive peripheral nerve stimulation (train-of-four ratio). Peripherally acting acetylcholinesterase inhibitors such as neostigmine should then only be administered when indicated and dosed based on results of the train-of-four ratio.